Hidradenitis Suppurativa clinical trials at UCLA
2 in progress, 1 open to eligible people
Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
open to eligible people ages 18-100
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of remibrutinib (LOU064) in adult participants with moderate to severe hidradenitis suppurativa (HS) who have completed either of the preceding Phase 3 studies, CLOU064J12301 or CLOU064J12302.
Sylmar, California and other locations
Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Sorry, in progress, not accepting new patients
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Sylmar, California and other locations
Our lead scientists for Hidradenitis Suppurativa research studies include April Armstrong.
Last updated: